All In MedTech

FDA Clearance Tracker · P210022

Alinity m CMV

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: May 5, 2022 (this decision)Source: openFDAMethods & limitations

PMA

Decided

May 5, 2022

Approved (reclassified)

Time to decision

338 days

Received Jun 1, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class II

The decision

FDA number
P210022
Device name
Alinity m CMV
Applicant location
Des Plaines, IL
Received
Jun 1, 2021
Decided
May 5, 2022
Decision
Approved (reclassified)
Supplements
12 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3180

Every decision under product code PAB

FDA's approval statement

As written in FDA's record.

Approval for Alinity m CMV. Alinity m CMV AMP KitThe Alinity m CMV assay is an in vitro polymerase chain reaction (PCR) assay for use with the automated Alinity m System to quantitate cytomegalovirus (CMV) DNA in human EDTA plasma. The Alinity m CMV assay is intended for use as an aid in the management of Hematopoietic Stem Cell Transplant and Solid Organ Transplant patients who are undergoing anti-cytomegalovirus therapy. The Alinity m CMV assay can be used to assess virological response to anti-cytomegalovirus therapy. The results from the Alinity m CMV test must be interpreted within the context of all relevant clinical and laboratory findings. The Alinity m CMV test is not intended as a screening test for the presence of CMV DNA in blood or blood products.Alinity m CTRL KitThe Alinity m CMV controls are for validity determination of the quantitative Alinity m CMV assay on the automated Alinity m System. These controls are intended to be used with the Alinity m CMV assay; refer to the assay package insert for additional information.Alinity m CAL KitThe Alinity m CMV calibrators are for calibration for the Alinity m CMV assay on the automated Alinity m System when used for the quantitative determination of CMV DNA. The calibrators are intended to be used with the Alinity m CMV assay; refer to the assay package insert for additional information.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PAB. The earliest in FDA's data is P110037, decided Jul 5, 2012.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Abbott Molecular, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.